K~2P~2.1(TREK-1)~cryst~ ([Extended Data Fig. 1a,b](#F5){ref-type="fig"}) crystallized alone and with activators, ML335 (N- \[(2,4-dichlorophenyl)methyl\]-4-(methanesulfonamido) benzamide) and ML402 (N- \[2- (4-chloro-2-methylphenoxy)ethyl\]thiophene-2-carboxamide), and diffracted X-rays to 3.1 Å, 3.0 Å and 2.8 Å, respectively ([Extended Data Table 1](#T1){ref-type="table"}) enabling structure determination ([Extended Data Fig. 1c](#F5){ref-type="fig"}). K~2P~2.1(TREK-1)~cryst~ has a domain-swapped M1 helix, extracellular CAP domain, and an unimpeded aqueous path between the intracellular side and selectivity filter, similar to prior TREK subfamily structures^[@R6],[@R13]--[@R15]^ ([Fig. 1a](#F1){ref-type="fig"}). Features absent in prior K~2P~ structures include a C-terminal tail (C-tail) five helical turns longer than in K~2P~10.1(TREK-2)^[@R6]^, Trp295-Val321 ([Fig. 1a](#F1){ref-type="fig"}, [Extended Data Fig. 1c](#F5){ref-type="fig"}), the 111-128 loop connecting the P1 pore helix and CAP bearing the extracellular pH sensor, His126^[@R16],[@R17]^ ([Fig. 1a](#F1){ref-type="fig"}, [Extended Data Fig. 1d](#F5){ref-type="fig"}), and a set of bound lipids ([Extended Data Fig. 1e,f](#F5){ref-type="fig"}).

Structures of the ML335 and ML402 complexes revealed unambiguous density for two activators per channel ([Fig. 1b](#F1){ref-type="fig"}, [Extended Data Fig. 2a--e](#F6){ref-type="fig"}) occupying an L-shaped pocket behind the selectivity filter formed by the P1 pore helix and M4 transmembrane helix intrasubunit interface ([Fig. 1c,d](#F1){ref-type="fig"}). Importantly, contrasting the activated mutant, K~2P~2.1(TREK-1) G137I^[@R7]^, K~2P~2.1(TREK-1)~cryst~ responds to both ML335 and ML402 ([Extended Data Fig. 2f--i](#F6){ref-type="fig"}). The ML335/ML402 binding pocket differs from the TREK antagonist norfluoxetine^[@R6]^ binding site ([Fig. 1e](#F1){ref-type="fig"}) and is dissimilar to other VGIC superfamily pore domain antagonist sites^[@R18],[@R19]^ ([Extended Data Fig. 3](#F7){ref-type="fig"}). Thus, the ML335/ML402 site, dubbed the 'K~2P~ modulator pocket', establishes a novel point for VGIC superfamily small molecule modulation.

The K~2P~ modulator pocket comprises a 'P1 face' and an 'M4 face' that form a common set of hydrogen bonds, π-π, and cation-π^[@R20]^ interactions with ML335 and ML402 ([Fig. 2a,b](#F2){ref-type="fig"} [Extended Data Fig. 4a,b](#F8){ref-type="fig"}). Both compounds adopt an L-shaped conformation enabling their 'upper ring' (ML335 *N*-aryl sulfonamide and ML402 thiophene) and 'lower ring' (ML335 dicholoro-benzyl and ML402 aryl ether) to engage the P1 helix residue Phe134 through face-face and edge-face interactions, respectively ([Fig. 2a,b](#F2){ref-type="fig"}). On the M4 face, the upper and lower rings make a cation-π interaction with Lys271 and edge-face interaction with Trp275, respectively ([Fig. 2](#F2){ref-type="fig"}, [Extended Data Fig 2a,b](#F6){ref-type="fig"}, and [4a,b](#F8){ref-type="fig"}). The amide groups of both compounds also make hydrogen bonds with the Ala259 carbonyl on the loop connecting the second selectivity filter. The ML335 sulfonamide forms additional interactions with the Gly260 carbonyl on the same loop, the P1 face Ser131 hydroxyl, the 111-128 loop His126 imidazole nitrogen, and Asn147 on the first selectivity filter ([Fig. 2a](#F2){ref-type="fig"}, [Extended Data Fig 4a](#F8){ref-type="fig"}).

The K~2P~ modulator pocket constitutes a cryptic binding site requiring conformational changes centered around Phe134, Lys271, and Trp275 ([Fig. 2c,d](#F2){ref-type="fig"}, [Extended Data Video V1](#SD5){ref-type="supplementary-material"}). Without activators, Phe134 and the M4 helix N-terminal end occlude the pocket. These elements move towards the selectivity filter and away from the P1 helix, respectively, to allow access. Lys271 and Trp275 are mobile in the unliganded structure ([Extended Data Fig. 5a](#F9){ref-type="fig"} and [6b](#F10){ref-type="fig"}), change conformation to form modulator interactions, and together with Phe134 have reduced bound state mobility ([Extended Data Fig. 5a--c](#F9){ref-type="fig"}, and [Table 2a](#T2){ref-type="table"}). Hence, both compounds act as wedges driven into the selectivity filter supporting structure, a mode reminiscent of other channel modulators^[@R21],[@R22]^. Notably, the K~2P~ modulator pocket includes GOF mutation sites, Gly137 and Trp275, affecting all TREK subfamily members^[@R7],[@R8],[@R15],[@R23]^ ([Extended Data Fig. 6b](#F10){ref-type="fig"}). Together, these observations indicate that the P1/M4 interface is a hub for conformational changes causing TREK subfamily activation and that P1/M4 interface stabilization is central to ML335 and ML402 action.

K~2P~ activator pocket residues that contact the compounds are identical among TREK subfamily members, except for the Lys271 cation-π interaction, and diverge in other K~2P~ subtypes ([Extended Data Fig. 4c,d](#F8){ref-type="fig"}). Comparison with K~2P~10.1(TREK-2)^[@R6]^ and K~2P~4.1(TRAAK)^[@R4],[@R13]--[@R15]^ ([Extended Data Fig. 6a](#F10){ref-type="fig"}, [Table 2b](#T2){ref-type="table"}) reveals no selectivity filter conformation differences. This structural similarity supports the idea that ML335 and ML402 influence selectivity filter dynamics, similar to inferences from structural studies of P1/M4 interface GOF mutants^[@R15]^. There are notable differences in the first two M4 helical turns of the K~2P~ modulator pocket and the conformations of the Phe134 and Trp275 equivalent positions among TREK subfamily structures ([Extended Data Fig. 6b--f](#F10){ref-type="fig"}). Given the varied conformations of these residues in the absence of activators and mobility changes between the unliganded and liganded structures ([Extended Data Fig. 5](#F9){ref-type="fig"}), the main action of the activator appears to be to limit the conformations sampled by P1/M4 interface elements.

The K~2P~2.1(TREK-1) C-tail senses phospholipid^[@R24],[@R25]^, phosphorylation^[@R26],[@R27]^, temperature^[@R7],[@R28]^, and pressure^[@R27]^ gating commands and forms a continuous helix with M4 ([Fig. 3a](#F3){ref-type="fig"}). Prior TREK subfamily structures uncovered varied M4 conformations spanning extremes termed 'up' and 'down'^[@R4],[@R6],[@R13]--[@R15]^. Proposals that the 'up'^[@R14]^, 'down'^[@R15]^, or both conformations are active ^[@R6],[@R23]^, have been advanced. In all K~2P~2.1(TREK-1) structures, M4 is 'up' ([Fig. 1a](#F1){ref-type="fig"}) and the selectivity filter sites S1--S4 are occupied by potassium ions ([Extended Data Fig. 6a](#F10){ref-type="fig"}). Because both C-tails make lattice contacts ([Extended Data Fig. 1g](#F5){ref-type="fig"}) that can influence M4^[@R13],[@R15]^, the K~2P~2.1(TREK-1) structures cannot directly address the controversy regarding M4 status. Nevertheless, the activator-bound selectivity filter is compatible with the 'up' M4 conformation.

The C-tail has two faces, an electropositive patch comprising four residues implicated in PIP~2~ modulation (Arg297, Lys301, Lys302, and Lys304)^[@R24],[@R25]^, and a face housing the intracellular proton sensor site, Glu306^[@R29]^, and inhibitory phosphorylation site, Ser300^[@R26]^ ([Fig. 3a,b](#F3){ref-type="fig"}). The channel electrostatic profile shows a second positively charged region at the M1/M2/M4 junction ([Fig. 3b](#F3){ref-type="fig"}) suggesting that the resultant interhelical groove may be a phospholipid binding site.

All three K~2P~2.1(TREK-1) structures revealed tubular densities at locations different from previous K~2P~ lipid binding sites^[@R4],[@R6],[@R14],[@R15]^, denoted as lipids L1, L2, and L3 ([Fig. 3c](#F3){ref-type="fig"}, [Extended Data Fig. 1e,f](#F5){ref-type="fig"}). L1 resides at the M2/P2 intersubunit junction ([Fig. 3c](#F3){ref-type="fig"}). L2 and L3 are part of a single phospholipid ([Extended Data Fig. 1e,f](#F5){ref-type="fig"}) and sit in the groove formed by the positively charged M1/M2/M4 intersubunit junction ([Fig. 3b and c](#F3){ref-type="fig"}, [Extended Data Fig. 1e,f](#F5){ref-type="fig"}). The L2/L3 site seems to be a prime point for modulatory lipids, as the positively charged residues that affect PIP~2~ responses^[@R24],[@R25]^ are on the helical face opposite to L2/L3 and M4 conformational changes could affect how these residues interact with regulatory lipid headgroups.

*Xenopus* oocyte two electrode voltage-clamp measurements show that ML335 and ML402 activate K~2P~2.1(TREK-1) and K~2P~10.1(TREK-2) but not K~2P~4.1(TRAAK) (14.3 ± 2.7 μM, K~2P~2.1(TREK-1):ML335; 13.7± 7.0 μM, K~2P~2.1(TREK-1):ML402; 5.2 ± 0.5 μM, K~2P~10.1(TREK-2):ML335; and 5.9 ± 1.6 μM, K~2P~10.1(TREK-2):ML402) ([Fig. 4a--f](#F4){ref-type="fig"}, [Extended Data Fig. 7a--c](#F11){ref-type="fig"}). The K~2P~ modulator pocket has a single difference among TREK subfamily members at the cation-π interaction position, K~2P~2.1(TREK-1) Lys271 ([Extended Data Fig. 4c](#F8){ref-type="fig"}), which is also a lysine in K~2P~10.1(TREK-2) but a glutamine in K~2P~4.1(TRAAK). Hence, we asked whether this residue controlled the selective actions of ML335 and ML402. Swapping the Lys271 equivalent between K~2P~2.1(TREK-1) and K~2P~4.1(TRAAK) resulted in a clear phenotype reversal for ML335 and M402 activation ([Fig. 4c and f](#F4){ref-type="fig"}, [Extended Data Fig. 7d--g](#F11){ref-type="fig"}). K~2P~2.1(TREK-1) K271Q was insensitive to ML335 and ML402, whereas K~2P~4.1(TRAAK) Q258K responded to both with a similar EC~50~ to K~2P~2.1(TREK-1) (14.3 ± 2.7 μM, K~2P~2.1(TREK-1):ML335; 16.2 ± 3.0 μM, K~2P~4.1(TRAAK) Q258K:ML335; 13.7± 7.0 μM, K~2P~2.1(TREK-1):ML402; 13.6 ± 1.5 μM, K~2P~4.1(TRAAK) Q258K:ML402) but with a lower magnitude response than K~2P~2.1(TREK-1). Notably, the effects of TREK subfamily activators arachidonic acid (AA)^[@R27],[@R30]^, BL-1249^[@R31],[@R32]^, and ML67-33^[@R11]^ were unchanged ([Extended Data Fig. 7h--k](#F11){ref-type="fig"}). To probe the cation-π interaction further, we synthesized a ML335 congener, ML335a, in which the aromatic upper ring was replaced with an aliphatic ring ([Fig. 4c](#F4){ref-type="fig"}). ML335a had no effect on K~2P~2.1(TREK-1) ([Fig. 4c](#F4){ref-type="fig"}), supporting the importance of the cation-π interaction. Together, these data identify the Lys271 cation-π interaction as the origin of ML335/ML402 subtype selectivity and establish that this interaction is essential for activation.

The principal K~2P~ channel gating site is the selectivity filter 'C-type' gate^[@R7]--[@R10]^. This gate is highly sensitive to permeant ions^[@R8],[@R16],[@R17]^ and is thought to function via 'flux gating' whereby outward, but not inward, ion flow stabilizes the active conformation^[@R9]^. Physiological K~2P~2.1(TREK-1) activators, such as AA, PIP~2~, and intracellular acidification, shift the channel from outward rectifier mode to an ohmic 'leak mode'^[@R9]^. Because K~2P~ modulator pocket contains architectural elements that support the selectivity and GOF mutant sites that activate the C-type gate^[@R7],[@R8],[@R15]^, we asked whether P1/M4 interface structural changes caused by ML335, ML402, or GOF mutation impact C-type gate function.

Measurement of K~2P~2.1(TREK-1) in inside-out patches under conditions that potentiate flux-dependent C-type gate activation (150 mM K^+^~\[out\]~ versus 150 mM Rb^+^~\[in\]~)^[@R9]^ showed the expected outward rectification ([Fig. 4g and k](#F4){ref-type="fig"}). ML335 and ML402 activate K~2P~2.1(TREK-1) in HEK293 cells similar to their effects in *Xenopus* oocytes (5.2 ± 0.8 μM and 5.9 ± 1.6 μM for ML335 and ML402, respectively (n≥3)) ([Fig. 4g--i](#F4){ref-type="fig"}, [Extended Data Fig. 8a](#F12){ref-type="fig"}). Compound application essentially eliminated flux-dependent outward rectification ([Fig. 4h,i, and k](#F4){ref-type="fig"}) yielding a rectification coefficient (I~+100mV~/I-~100mV~) of \~1. This outcome matches physiological activator effects^[@R9]^ and establishes that ML335 and ML402 activate the C-type gate. The K~2P~4.1(TRAAK) GOF mutation G124I reshapes the K~2P~ modulator pocket through structural consequences similar to ML335/ML402, namely an outward M4 movement and repositioning of the K~2P~2.1(TREK-1) Phe134 equivalent residue^[@R15]^ ([Extended Data Fig. 6f](#F10){ref-type="fig"}). K~2P~2.1(TREK-1) G137I and K~2P~4.1(TRAAK) G124I^[@R7],[@R15]^ caused a similar mode shift and rectification coefficient change to ML335 and ML402 ([Fig. 4j and k](#F4){ref-type="fig"}, [Extended Data Fig. 8b--d](#F12){ref-type="fig"}) establishing that K~2P~ modulator pocket manipulation by ML335/ML402 binding or mutation directly activates the selectivity filter C-type gate. Together with the compound binding induced mobility reduction of the P1/M4 interface ([Extended Data Fig. 5](#F9){ref-type="fig"}) and lack of K~2P~ selectivity filter structural differences ([Extended Data Fig. 6a](#F10){ref-type="fig"}), our findings strongly support the idea that direct C-type gate activators stimulate function by reducing the dynamics of the selectivity filter and surrounding structure.

The roles of TREK channels in ischemia, pain, analgesia, and anesthetic responses^[@R1]^ suggests that TREK activators could provide new avenues for neuroprotection and pain control. Many natural TREK regulators are thought to act on the C-tail^[@R7],[@R24]--[@R29]^ and influence the C-type gate through M4 ^[@R6]--[@R8],[@R15],[@R23]^ whose movement is targeted by the antagonist norfluoextine^[@R6],[@R23]^. In this regard, ML335 and ML402 represent a new K~2P~ modulator class, as they function by binding directly to a pocket at the heart of the channel active site, the C-type gate, rather than influencing the C-tail or M4.

The K~2P~ modulator pocket defines the first VGIC superfamily pore domain small molecule activator site and differs from antagonist sites occupying lateral fenestrations below the selectivity filter^[@R6],[@R18]^ ([Fig. 1e](#F1){ref-type="fig"}, [Extended Data Fig. 3a](#F7){ref-type="fig"}). Voltage-gated calcium channel antagonists, amlodipine and nifedipine^[@R19]^, act at an interface similar to the K~2P~ modulator pocket, but at a pore domain outer rim site normally occupied by lipids^[@R19]^ ([Extended Data Fig. 3b](#F7){ref-type="fig"}). Notably, all of these small molecule sites are found at interfaces that are thought to move during gating^[@R6],[@R18],[@R19]^, highlighting the potential of channel intersubunit interfaces as small molecule control sites.

Our findings provide a structural basis for understanding K~2P~ C-type gate activation. The K~2P~ modulator pocket in unliganded K~2P~2.1(TREK-1) displays mobility in key elements that is reduced upon activator engagement ([Fig. 4l](#F4){ref-type="fig"}, [Extended Data Figs. 5](#F9){ref-type="fig"}, [6b--d](#F10){ref-type="fig"}, and [Video V1](#SD5){ref-type="supplementary-material"}). Notably, the K~2P~ modulator pocket M4 helix N-terminal end, an important site for channel activation^[@R8]^ and conduit for transmitting C-tail sensor domain cues to the C-type gate^[@R7],[@R8]^, adopts a similar position in the ML335 and ML402 K~2P~2.1(TREK-1) complexes and in K~2P~4.1(TRAAK) G124I ([Extended Data Fig. 6f](#F10){ref-type="fig"}). As the remainder of M4 is 'up' for the K~2P~2.1(TREK-1) activator complexes, but 'down' for K~2P~4.1(TRAAK) G124I, the data support the idea that M4 position is not the sole determinant of channel state^[@R23]^. The importance of changes in P1/M4 interface dynamics explain how M4 can affect channel function and allow the 'up' or 'down' conformations to activate the channel^[@R23]^, as both states could limit the mobility of the P1/M4 interface. Such plasticity may be important for enabling TREK subfamily polymodal modulation. Our findings indicate that under basal conditions, K~2P~2.1(TREK-1) equilibrates between a resting state having a mobile P1/M4 interface and an activated state in which the mobility of this site is limited. ML335 and ML402 directly stabilize the C-type gate by acting like molecular wedges that reduce P1/M4 interface dynamics ([Fig. 4l](#F4){ref-type="fig"}, [Extended Data Fig. 5](#F9){ref-type="fig"} and [Table 2a](#T2){ref-type="table"}) and cause the filter to enter the 'leak mode' ([Fig. 4h, i](#F4){ref-type="fig"}), bypassing modulation mechanisms that may involve other channel regions. The K~2P~ modulator pocket properties revealed by our studies raise the possibility that natural processes or native signaling molecules may also target this site.

Opening the cryptic K~2P~ modulator pocket requires small movements of few residues, similar to soluble protein cryptic modulator sites^[@R33]^. K~2P~ modulator pocket diversity ([Extended Data Fig. 4c,d](#F8){ref-type="fig"}), the P1/M4 interface susceptibility to GOF mutations^[@R7],[@R8]^, and demonstration that a single residue therein can define modulator selectivity suggests that this site may be amenable for K~2P~ subtype-selective pharmacology development. As the fundamental pocket architecture is conserved in the VGIC superfamily, similar modulatory mechanisms may exist in other superfamily members where selectivity filter based gating is central. Thus, this site should provide a fertile target for channel modulator discovery.

Methods {#S1}
=======

No statistical methods were used to predetermine sample size. No randomization or blinding was used.

Construct screening {#S2}
-------------------

A set of mutants and deletion constructs of mouse K~2P~2.1(TREK-1)^[@R1]^ bearing a C-terminal TEV protease cleavage site and GFP were expressed from a pcDNA3.1 in HEK293 cells and screened for expression level and peak quality using Fluorescence-detection Size Exclusion Chromatography (FSEC)^[@R39]--[@R41]^. These efforts identified a construct, hereafter called K~2P~2.1(TREK-1)~cryst~, encompassing residues 21-322 and bearing the following mutations: K84R, Q85E, T86K, I88L, A89R, Q90A, A92P, N95S, S96D, T97Q, N119A, S300A, E306A. The first nine mutations are located on the surface of the CAP domain and greatly increased expression. N119A targets a putative glycosylation site. S300A and E306A are previously studied mutants^[@R7]^ that improved the biochemical properties of the purified protein. The reduced response of K~2P~2.1 (TREK-1)~cryst~ to ML335 and ML402 likely results from partial activation of the channel in a cellular context due to the incorporation of the E306A mutation^[@R7],[@R29]^ and is compatible with the model proposed in [Fig. 4l](#F4){ref-type="fig"} in which basal activity is increased by E306A but can nevertheless be shifted to the C-type gate activated state by activator binding and C-type gate stabilization.

Protein Expression {#S3}
------------------

K~2P~2.1(TREK-1)~cryst~ bearing a C-terminal green fluorescent protein (GFP) and His~10~ tag was expressed from a previously described *P. pastoris* pPICZ vector^[@R4]^. Plasmids were linearized with *PmeI* and transformed into *P. pastoris* SMD1163H by electroporation. Multi-integration recombinants were selected by plating transformants onto Yeast Extract Peptone Dextrose Sorbitol (YPDS) plates having increasing concentrations of zeocin (1--4 mg ml^−1^). Expression levels of individual transformants were evaluated by FSEC as previously described^[@R15]^.

Large-scale expression was carried out in a 7L Bioreactor (Labfors5, Infors HT). First, a 250 ml starting culture was grown in buffered minimal medium (2x YNB, 1% Glycerol, 0.4 mg L^−1^ biotin, 100 mM potassium phosphate, pH 6.0) in shaker flasks for two days at 29°C. Cells were pelleted by centrifugation (3000 x g, 10', 20°C) and used to inoculate the bioreactor. Cells were grown in minimal medium (4% glycerol, 0.93 g L^−1^ CaSO~4~.2H~2~O, 18.2 g L^−1^ K~2~SO~4~, 14.9 g L^−1^ MgSO~4~.7H~2~O, 9 g L^−1^ (NH~4~)~2~SO~4~, 25g L^−1^ Na^+^ hexametaphosphate, 4.25ml L^−1^ PTM~1~ trace metals stock solution prepared accordingly to standard Invitrogen protocol) until the glycerol in the fermenter was completely metabolized marked by a spike in pO~2~ (\~24 hours). Fed-batch phase was then initiated by adding a solution of 50% glycerol and 12ml L^−1^ of trace metals at 15%--30% of full pump speed until the wet cell mass reached \~250 g L^−1^ (\~24 hours). pO~2~ was measured continuously and kept at a minimum of 30%. Feed rate was automatically regulated accordingly. pH was maintained at 5.0 by the addition of a 30% ammonium hydroxide solution.

After the fed-batch phase was completed, cells were then starved to deplete glycerol by stopping the feeder pump until a pO~2~ spike appeared. After starvation, the temperature was set to 27°C, and the induction was initiated with addition of methanol in three steps: (1) Initially, the methanol concentration was kept at 0.1% for 2 h in order to adapt the cells. (2) Methanol concentration was then increased to 0.3% for 3h, and (3) methanol was then increased to 0.5% and expression continued for \~48--60 hours. Cells were then pelleted by centrifugation (6000 x g,1h, 4°C), snap frozen in liquid nitrogen, and stored at −80°C.

Protein Purification {#S4}
--------------------

In a typical preparation, 50 g of cells were broken by cryo-milling (Retsch model MM400) in liquid nitrogen (5 x 3 min, 25 Hz). All subsequent purification was carried out at 4° C. Cell powder was added at a ratio of 1g cell powder:3ml lysis buffer (200 mM KCl, 21 mM OGNG \[Octyl Glucose Neopentyl Glycol, Anatrace\], 30 mM HTG \[n-heptyl-β-D-thioglucopyranoside, Anatrace\], 0.1% CHS, 0.1 mg mL^−1^ DNAse 1 mM PMSF, 100 mM Tris-Cl, pH 8.2). Membranes were extracted for 3 hours with gentle stirring followed by centrifugation at (100000 x g, 45' at 4°C).

Solubilized proteins were purified by affinity chromatography using batch purification. Anti-GFP nanobodies were conjugated with CNBr Sepharose beads (GE Healthcare, \#17-0430-02) according to reference ^[@R42]^. The resin was added to the cleared supernatant at a ratio of 1 ml of resin per 10 g of cell powder and incubated at 4°C for 3h with gentle shaking. Resin was collected into a column and washed with 10 column volumes (CV) of buffer A (200 mM KCl, 10 mM OGNG, 15 mM HTG, 0.018% CHS, 50 mM Tris-Cl, pH8.0) followed by a second wash step using 10 CV of buffer B containing (200 mM KCl, 5 mM OGNG, 15 mM HTG, 0.018% CHS, 50 mM Tris-Cl, pH8.0). The resin was then washed with additional 10 CV of buffer C (200 mM KCl, 3.85 mM OGNG, 15 mM HTG, 0.0156% CHS, 50 mM Tris-Cl, pH 8.0). On column cleavage of the affinity tag was achieved by incubating the resin with buffer C supplemented to contain 350 mM KCl, 1 mM EDTA, and 3C protease^[@R43]^ at ratio of 50:1 resin volume:protease volume. The resin was incubated overnight at 4°C. Cleaved sample was collected and the resin washed with 2 CV of SEC buffer (200 mM KCl, 2.1 mM OGNG, 15 mM HTG, 0.012% CHS, 20 mM Tris-Cl, pH 8.0). Purified sample was concentrated and applied to a Superdex 200 column equilibrated in SEC buffer.

Crystallization and Refinement {#S5}
------------------------------

Purified K~2P~2.1(TREK-1)~cryst~ was concentrated to 6 mg ml^−1^ by centrifugation (Amicon® Ultra-15, 50 kDa molecular mass cutoff; Millipore) and crystallized by hanging-drop vapor diffusion at 4°C using a mixture of 0.2 μl of protein and 0.1 μl of precipitant over 100 μl of reservoir containing 20--25% PEG400, 200 mM KCl, 100 mM HEPES pH 8.0, 1 mM CdCl~2~. Crystals appeared in 12 hours and grew to full size (200μm-300μm) in about a week. Crystals were cryoprotected with buffer D (200 mM KCl, 0.2% OGNG, 15 mM HTG, 0.02% CHS, 100 mM HEPES pH 8.0,1 mM CdCl~2~) with 5% step increase of PEG400 up to a final concentration of 38% and flash frozen in liquid nitrogen.

K~2P~2.1(TREK-1)~cryst~ ML335 and ML402 complex crystals grew in the same conditions as K~2P~2.1(TREK-1)~cryst~, but the protein was incubated for at least 1h with 2.5mM of activator before setting the crystal plates. ML335 and ML402 are insoluble in aqueous solutions, so they were dissolved in 100% DMSO at a concentration of 500 mM. Then each compound was diluted 1:100 in SEC buffer to 5 mM concentration, giving a milky solution. This solution was mixed 1:1 to K~2P~2.1(TREK-1)~cryst~ previously concentrated to 12 mg ml^−1^. The K~2P~2.1(TREK-1)~crys~ /ML402 mixture resulted in a clear solution, while the mixture with ML335 was slightly milky. The samples were briefly centrifuged in a table top centrifuge (10.000 x g) to remove any insoluble material before setting the crystal plates.

Datasets for K~2P~2.1(TREK-1), K~2P~2.1(TREK-1):ML335, and K~2P~2.1(TREK-1):ML402 were collected at 100 K using synchrotron radiation at ALS Beamline 8.3.1 Berkeley, CA and APS GM/CAT beamline 23-IDB/D Chicago, IL using wavelengths of 1.1159Å and 1.0332Å, respectively, processed with XDS^[@R44]^, scaled and merged with Aimless^[@R45]^. Final resolution cutoff was 3.1Å and 3.0 Å and 2.8 Å for K~2P~2.1(TREK-1)~cryst~, K~2P~2.1(TREK-1)~cryst~:ML335, and K~2P~2.1(TREK-1)~cryst~:ML402, respectively, using the CC~1/2~ criterion^[@R46],[@R47]^. Structures were solved by molecular replacement using the K~2P~4.1(TRAAK) G124I structure (PDB 4RUE)^[@R15]^ as search model. Several cycles of manual rebuilding, using COOT^[@R48]^, and refinement using REFMAC5^[@R49]^ and PHENIX^[@R50]^ were carried out to improve the electron density map. Two-fold local medium NCS restraints were employed during refinement for residues 28-103, 110-158 and 194-260.

K~2P~2.1(TREK-1), K~2P~2.1(TREK-1):ML335, and K~2P~2.1(TREK-1):ML402 structures have, respectively, 95.2%/0.4%, 92.0%/0.5% and 95.7%/0.4% residues in favored regions/outliers of the Ramachandran plot as assessed by Molprobity^[@R51]^.

Electrophysiology {#S6}
-----------------

### Patch-clamp electrophysiology {#S7}

mouse K~2P~2.1(TREK-1), human K~2P~4.1(TRAAK), and mutants were expressed from a previously described pIRES2-EGFP vector^[@R8],[@R11]^ in HEK 293T cells (ATTC). 70% confluent cells were transfected (in 35 mm diameter wells) with LipofectAMINE^™^ 2000 (Invitrogen, Carlsbad, CA, USA) for 6 hours, and plated onto coverslips coated with Matrigel (BD Biosciences, San Diego, CA, USA).

Effects of ML335, ML402, and arachidonic acid on K~2P~2.1(TREK-1) current at 0 mV were measured by whole cell patch-clamp experiments 24 hours after transfection. Acquisition and analysis were performed using pCLAMP9 and an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA). Pipette resistance ranged from 1 to 1.5 MΩ. Pipette solution contained the following, in millimolar: 145, KCl; 3, MgCl~2~; 5, EGTA and 20, HEPES (pH 7.2 with KOH). Bath solution contained the following, in millimolar: 145, NaCl; 5, KCl; 1, CaCl~2~; 3, MgCl~2~; 20, HEPES (pH 7.4 with NaOH). K~2P~2 (TREK-1) currents were elicited by a 1 second ramp from --100 to +50 mV from a --80 mV holding potential. After stabilization of the basal current, ML335 and ML402 were perfused at 200 ml hr^−1^ until potentiation was stably reached.

Voltage-dependent activation of K~2P~2.1(TREK-1) was recorded on excised patches in inside-out configuration (50kHz sampling) in the absence and presence of 5 μM ML335 or ML402. Pipette solution contained the following, in millimolar: 150 KCl; 3.6 CaCl~2~; 10 HEPES (pH 7.4 with KOH). Bath solution contained the following, in millimolar: 150 RbCl; 2 EGTA and 10 HEPES (pH 7.4 with RbOH), and was continuously perfused at 200 ml hr^−1^ during the experiment. TREK-1 currents were elicited by a voltage step protocol from −100mV to +100mV, from a --80 mV holding potential (or −10mV for K~2P~2.1(TREK-1) G137I and K~2P~4.1(TRAAK) G124I in presence of the compounds after exposing the patch to the compound for 30 s at −80 mV). Data were analyzed using Clampfit 9 and Origin 7.

### Two Electrode Voltage Clamp Electrophysiology {#S8}

Two electrode voltage clamp recordings were performed on defolliculated stage V--VI *Xenopus laevis* oocytes 24--48 h after microinjection with 0.15--5 ng cRNA. Oocytes were impaled with borosilicate recording microelectrodes (0.3--3.0MΩ resistance) backfilled with 3M KCl. Recording solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl~2~, and 2.0 mM MgCl~2~, buffered with 5 mM HEPES, pH 7.4) was perfused at a rate of 3 ml min^−1^.

Currents were evoked from a −80mV holding potential followed by a 300 ms ramp from −150 mV to +50 mV. Data were acquired using a GeneClamp 500B amplifier (MDS Analytical Technologies) controlled by pClamp software (Molecular Devices), and digitized at 1 kHz using Digidata 1332A digitizer (MDS Analytical Technologies).

Dose-response experiments were carried by first preparing a DMSO stock solution of each activator at a concentration of 100 mM. Due to the low solubility of the compounds the highest tested concentrations in recording solution were 100 μM and 80 μM for ML335 and ML402, respectively (final concentration of DMSO was 0.2%). Other concentrations were prepared by serial dilutions of the 100 μM solution in recording buffer supplemented with 0.1% DMSO.

*Xenopus* oocytes were collected incompliance with ethical regulations specified by the UCSF Institutional Animal Care and Use Committee protocol AN129690.

### Synthetic chemistry {#S9}

Detailed descriptions of synthesis routes and characterization of ML335, ML335a, and ML402 are found in the [supplementary material](#SD1){ref-type="supplementary-material"}.

Extended Data {#S10}
=============

![K~2P~2.1(TREK-1)~cryst~ function and structure\
**a,** Exemplar recording from K~2P~2.1(TREK-1)~cryst~ expressed in *Xenopus* oocytes. Current was elicited from a −80mV holding potential followed by a 500 ms ramp from −150 mV to +50 mV. **b**, K~2P~2.1(TREK-1)~cryst~ potassium selectivity recorded in *Xenopus* oocytes in K^+^/N-methyl-D-glucamine solutions (98.0 mM total) at pH~o~= 7.4. Data represent mean ± SEM (n= 4). Dashed gray line represents Nernst equation E~rev~=RT/F\*log(\[K^+^\]~o~/\[K^+^\]~i~), where R and F have their usual thermodynamic meanings, z is equal to 1, and T=23°C, assuming \[K^+^\]~I~ = 108.6 mM^[@R34]^. **c,** Exemplar 2F~o~-F~c~ electron density (1.0 σ) for the C-tail region of K~2P~2.1(TREK-1)~cryst~. Select residues and channel elements are indicated. **d,** Extracellular view of K~2P~2.1(TREK-1)~cryst~ showing environment of His126 and Ile148 (raspberry). Select residues are labeled. The extracellular proton sensor His126^[@R16],[@R17]^ is supported by a highly conserved residue, Trp127, and contacts a gain-of-function (GOF) mutant site, Ile148^[@R8]^, that interacts with the selectivity filter residue Asn147. This network of physical interactions indicates how changes at His126^[@R16],[@R17]^ or Ile148^[@R8]^ could affect the C-type gate. **e,** and **f,** Exemplar L2/L3 lipid electron density for K~2P~2.1(TREK-1):ML335. **e,** 2Fo-Fc, (blue, 1.0 σ) and **f,** F~o~-F~c~, (hotpink, 3.0 σ). Chains are colored smudge and light orange. Channel elements and select residues are labeled. **g,** Crystal lattice packing for K~2P~2.1(TREK-1)~cryst~ showing that the C-tail makes lattice interactions stabilized by a cadmium ion coordinated between His313 of adjacent symmetry mates. Asymmetric unit is colored smudge (chain A) and light orange (chain B). Symmetry related channels are shown in slate (chain A) and cyan (chain B). Insets show the anomalous difference map (5.0σ) and locations of Cd^2+^ ions and their ligands.](nihms876351f5){#F5}

![K~2P~2.1(TREK-1)~cryst~ modulator binding pocket densities and K~2P~2.1(TREK-1)~cryst~ functional properties\
**a--e**, Exemplar electron densities for the modulator binding pockets. a--c, 2F~o~-F~c~ densities (blue) for a, K~2P~2.1(TREK-1):ML335 (1.5 σ), b, K~2P~2.1(TREK-1):ML402 (1.0 σ), and c, K~2P~ 2.1(TREK-1) (1.0 σ). Offset angle for the cation-π interactions for Lys271:ML335 and Lys271:ML402 is shown and adopts an oblique geometry common to cation-π interactions^[@R35],[@R36]^. d, and e, F~o~-F~c~ densities (hotpink, 3.0 σ) for d, K~2P~2.1(TREK-1):ML335 and e, K~2P~2.1(TREK-1):ML402. Final models are shown in all panels and select residues are shown and labeled. f--h, Exemplar current traces for f, K~2P~2.1 (TREK-1)~cryst~ (black) with 40 μM ML335 (yellow orange), g, K~2P~2.1 (TREK-1)~cryst~ (black) with 80 μM ML402 (green), and h, K~2P~2.1 (TREK-1) G137I (black) with 80 μM ML335 (blue). i, Dose response curves for K~2P~2.1(TREK-1):ML335 (black), EC~50~=14.3 ± 2.7 μM (n≥5); K~2P~2.1 (TREK-1)~cryst~:ML335, EC~50~ = 10.5 ± 2.7 μM (n≥3) (yellow orange) K~2P~2.1 (TREK-1)~cryst~:ML402, EC~50~ = 14.9 ± 1.6 μM (n≥3); and K~2P~2.1(TREK-1) G137I:ML335 (blue ).](nihms876351f6){#F6}

![Comparison of K~2P~ modulator and VGIC antagonist sites\
**a,** Superposition of the K~2P~2.1(TREK-1):ML335 complex (smudge and light orange) with the BacNa~V~ 'pore-only' Na~V~Ms structure^[@R18]^ (magenta and warm pink). Bromine site (Br) from labeled sodium channel antagonists is shown as a firebrick sphere. **b,** Superposition of the pore domains of the K~2P~2.1(TREK-1):ML335 complex (smudge and light orange) with the pore domain of the BacNa~V~ Ca~V~Ab (5KMD) bound to the inhibitor amlodipine (AMLOD)^[@R19]^, a site normally occupied by lipid^[@R19],[@R37]^. Select residues of the K~2P~ modulator pocket are shown as sticks and are labeled. Ca~V~Ab subunits are colored cyan, marine, slate, and dark blue. ML335 (yellow) and amlodipine (cyan) are shown in space filling representation.](nihms876351f7){#F7}

![K~2P~ modulator pocket structure and conservation\
Details of **a**, ML335, and **b**, ML402 interactions with K~2P~2.1(TREK-1). **c** and **d**, Representative K~2P~ channel sequence comparisons for the **c**, M4 face and **d**, P1 face. Purple bar and orange shading on sequence identifiers denotes the thermo- and mechanosensitive K~2P~2.1(TREK-1) subfamily. Protein secondary structure is marked above the sequences. Selectivity filter region is in red. Residues involved in direct interactions with ML335 and ML402 are orange and marked with an orange asterisk. Conserved positions are highlighted. K~2P~2.1(TREK-1) is the mouse protein used for this study. K~2P~2.1H(TREK-1) is the human homolog. All other K~2P~ sequences are human origin. Sequences and identifiers are as follows: K~2P~2.1(TREK-1) NP_034737.2; K~2P~2.1H(TREK-1), NP_001017424.1; K~2P~10.1(TREK-2), NP_612190.1; K~2P~4.1(TRAAK), NP_001304019.1; K~2P~3.1(TASK-1), NP_002237.1; K~2P~9.1(TASK-3), NP_001269463.1; K~2P~5.1(TASK-2), NP_003731.1; K~2P~1.1(TWIK-1), NP_002236.103812.2; K~2P~6.1(TWIK-2), NP_004823.1; K~2P~7.1(KCNK7), AAI03812.2; K~2P~16.1(TALK-1), NP_001128577.1; K~2P~17.1(TALK-2), NP_113648.2; K~2P~12.1(THIK-2), NP_071338.1; K~2P~12.1(THIK-1), NP_071337.2; K~2P~15.1(TASK-5), NP_071753.2; and K~2P~18.1(TRESK), NP_862823.1. '●' in K~2P~16.1(TALK-1) sequence in '**c**' denotes the following, non-conserved sequence that was removed to avoid a long alignment gap: NFITPSGLLPSQEPFQTPHGKPESQQIP.](nihms876351f8){#F8}

![K~2P~ structure comparisons\
K~2P~ modulator pocket views colored by B-factor for **a,** K~2P~2.1(TREK-1), **b,** K~2P~2.1(TREK-1):ML335**,** and **c,** K~2P~2.1(TREK-1):ML402. Bars show B-factor scale.](nihms876351f9){#F9}

![K~2P~ structure comparisons\
**a,** Backbone atom superposition of K~2P~2.1(TREK-1) (smudge, up), K~2P~2.1(TREK-1):ML335 (yellow, up), K~2P~2.1(TREK-1):ML402 (cyan, up), K~2P~10.1(TREK-2) (4BW5) (pink, up)^[@R6]^, K~2P~10.1(TREK-2) (4XDJ) (magenta, down)^[@R6]^, K~2P~10.1(TREK-2):Norfluoxetine (4XDK)(violet purple, down)^[@R6]^, K~2P~4.1(TRAAK) (4I9W) (limon, up)^[@R13]^, K~2P~4.1(TRAAK) G124I (4RUE) (marine, down)^[@R15]^, and K~2P~4.1(TRAAK) W262S (4RUF) (lime, down)^[@R15]^. 'up' or 'down' denotes M4 conformation. Selectivity filter ions for K~2P~2.1(TREK-1) (smudge), K~2P~2.1(TREK-1):ML335 (yellow), and K~2P~2.1(TREK-1):ML402 (cyan) are shown as spheres. ML335 and ML402 are shown in sticks. Select channel elements are labeled. **b--e,** Superposition showing **b,** K~2P~2.1(TREK-1) chain A (smudge) and chain B (light orange). Sites of GOF mutations, G137I (orange)^[@R7]^, and Trp275^[@R8]^, are indicated. **c,** K~2P~2.1(TREK-1):ML335 chain A (pink) and chain B (deep salmon), **d,** K~2P~2.1(TREK-1):ML402 chain A (cyan) and chain B (deep teal). **e,** K~2P~2.1(TREK-1) chain A (smudge) and chain B (light orange), K~2P~10.1(TREK-2) (4BW5) (pink)^[@R6]^, K~2P~10.1(TREK-2) (4XDJ) (magenta)^[@R6]^, K~2P~10.1(TREK-2):Norfluoxetine (4XDK)(violet purple)^[@R6]^. **f,** K~2P~2.1(TREK-1):ML335 (deep salmon), K~2P~4.1(TRAAK) (4I9W) (limon)^[@R13]^, K~2P~4.1(TRAAK) G124I (4RUE) (marine)^[@R15]^, K~2P~4.1(TRAAK) W262S (4RUF) (lime)^[@R15]^. G124I from K~2P~4.1(TRAAK) G124I^[@R15]^ is shown in sticks. In **b--f**, Phe134, His126, Lys271, Trp275, their equivalents in K~2P~10.1(TREK-2), K~2P~4.1(TRAAK), and K~2P~4.1(TRAAK) G124I, are shown in sticks. ML335, '**c'**, and ML402, **'d'**, are shown as sticks.](nihms876351f10){#F10}

![K~2P~ activator responses\
Exemplar current traces for **a,** K~2P~10.1(TREK-2) (black) with 20 μM ML335 (yellow orange) and **b,** K~2P~10.1(TREK-2) (black) with 20 μM ML402 (cyan). **c,** Dose response curves for K~2P~10.1(TREK-2) with ML335 (EC~50~ = 5.2 ± 0.5 μM (n\>3)) (yellow orange) and ML402 (EC~50~ = 5.9 ± 1.6 μM (n≥4)(cyan). Exemplar current traces for **d,** K~2P~2.1(TREK-1) K271Q (black) and with 20 μM ML335 (purple). **e,** K~2P~4.1(TREK-1) Q258K (black) and with 50 μM ML335 (orange). **f,** K~2P~2.1(TREK-1) K271Q (black) and with 50 μM ML402 (purple). **g,** K~2P~4.1(TREK-1) Q258K (black) and with 50 μM ML402 (orange). Currents were evoked from *Xenopus* oocytes expressing the indicated channels from a −80 mV holding potential followed by a 500 ms ramp from −150 mV to +50 mV. Compound structures are shown. **h,** and **i,** Exemplar current traces for HEK293 cell inside-out patches expressing **h,** K~2P~2.1(TREK-1) and **i,** K~2P~2.1(TREK-1) K271Q to stimulation by 10 μM arachidonic acid (AA) (green). **j,** Current potentiation measured in HEK cells at 0 mV in response to 10μM AA for K~2P~2.1(TREK-1) (n=5) and K~2P~2.1(TREK-1) K271Q (n=4). **k,** Current potentiation measured in *Xenopus* oocytes at 0 mV for K~2P~4.1(TRAAK) (white), K~2P~2.1(TREK-1) (black), K~2P~4.1(TRAAK) Q258K (cyan) and K~2P~2.1(TREK-1) K271Q (gray) in response to 10 μM BL-1249, 30 μM ML67-33, and 20 μM ML335. For all experiments (n≥4). Data are mean ± SEM.](nihms876351f11){#F11}

![K~2P~ channel patch clamp recordings\
**a,** Dose response for K~2P~2.1(TREK-1) to ML335 (black circles) and ML402 (open circles) measured in HEK293 cells by whole cell patch clamp. EC~50~ values are 5.2 ± 0.8 μM and 5.9 ± 1.6 μM for ML335 and ML402, respectively (n≥3). **b,** and **c,** Representative current traces and voltage-current relationship from HEK293 inside-out patches for expressing **b,** K~2P~4.1(TRAAK) and **c,** K~2P~4.1(TRAAK) G124I elicited by a 350 ms-voltage step protocol from −100 mV to +100 mV in 150 mM K^+^~\[out\]~/150 mM Rb^+^~\[in\]~. **d,** Rectification coefficients (I~+100mV~/I-~100mV~) calculated from n≥3 current recordings obtained from the same conditions in '**b**' and '**c**'.](nihms876351f12){#F12}

###### 

Data collection and refinement statistics

                        K~2p~2.1 (TREK-1) (5VK5)      K~2p~2.1 (TREK-1): ML335 (5VKN)   K~2p~2.1 (TREK-1):ML402 (5VKP)
  --------------------- ----------------------------- --------------------------------- --------------------------------
  **Data collection**                                                                   
  Space group           *P*2~1~2~1~2~1~               *P*2~1~2~1~2~1~                   *P*2~1~2~1~2~1~
  Cell dimensions                                                                       
   *a, b, c* (Å)        66.72/120.42/126.44           67.07/119.39/128.18               67.09/119.56/127.21
   *α, β, γ* (°)        90.0/90.0/90.0                90.0/90.0/90.0                    90.0/90.0/90.0
  Resolution (Å)        87.2 -- 3.10 (3.21 -- 3.10)   87.4 -- 3.0 (3.11 -- 3.0)         87.1 -- 2.8 (2.99 -- 2.8)
  R~sym~ (%)            10.38 (\>100%)                23.7 (\>100%)                     14.2 (\>100%)
  *l*/σ(*l*)            13.35 (0.3)                   9.78 (0.66)                       11.13 (0.37)
  *CC*~1/2~             0.999 (0.065)                 0.998 (0.171)                     0.999 (0.108)
  Completeness (%)      97.0 (100.0)                  97.0 (100.0)                      98.0 (100.0)
  Redundancy            6.0 (6.2)                     12.9 (13.3)                       12.8 (13.6)
  **Refinement**                                                                        
  Resolution (Å)        15.0 -- 3.10 (3.21 -- 3.10)   15.0 -- 3.0 (3.11 -- 3.0)         15.0 -- 2.8 (2.99 -- 2.8)
  No. reflections       18506                         20686                             25882
  *R*~work~/*R*~free~   26.1/31.4                     25.8/28.3                         26.9/31.4
  No. atoms                                                                             
   Protein              4289                          4357                              4328
   Ligand/ion           74                            200                               174
  K^+^                  6                             6                                 6
  Cd^2+^                3                             3                                 1
  Lipid                 65                            191                               167
  ML335 or ML402                                                                        
   Water                0                             0                                 0
  *B* factors                                                                           
   Protein              154.6                         107.4                             147.7
   Ligand/ion           168.7                         96.5                              131.0
   Water                n/a                           n/a                               n/a
  R.m.s. deviations                                                                     
   Bond lengths (Å)     0.002                         0.006                             0.002
   Bond angles (°)      0.480                         0.685                             0.483

Values in parentheses are for highest-resolution shell.

each dataset was derived from a single crystal

###### 

K**~2P~2.1(TREK-1) B-factor and structure comparisions a,** B-factor comparisons. Selectivity filter residue B-factors are below the average channel core B-factor in both the K~2P~2.1(TREK-1) and modulator bound structures. Modulator pocket residue B-factors drop relative to the average B-factor in both the ML335 and ML402 complexes, indicating that modulator binding reduces the mobility of these residues. The structures are determined in \~200 mM potassium, a concentration that is expected to stabilize the conformation of the selectivity filter (cf. Ref. ^[@R38]^) and that could mask mobility changes. Average B-factor is calculated using the channel core elements on both chains: M1 (residues 47-65), P1 through common part of M2 (residues 127-188), common part of M3 through common part M4 (residues 210-300). The selectivity filter was included in the calculation. Blue and red values are \>10% below or above the average B-factor, respectively. **b,** K~2P~ channel structure comparisons. RMSDs are calculated using the following K~2P~2.1(TREK-1) (5VK5) Chain A and Chain B elements: (Δ*CAP*, Δ*M4*) M1 through CAP (residues 47-69), P1 through common part of M4 (residues 127-281). *Channel core (*Δ*CAP,* Δ*M2,* Δ*M4*) M1 (residues 47-65), P1 through common part of M2 (residues 127-188), common part of M3 through common part M4 (residues 210-300). The selectivity filter was included in the calculation. For the non-domain-swapped K~2P~4.1(TRAAK)(3UM7), residues 47-69 of chain A were compared to equivalent chain B residues.

  Extended Data Table 2a \| B-factor comparisons for K~2P~2.1(TREK-1) and modulator complexes                            
  --------------------------------------------------------------------------------------------- -------- ------- ------- -------
  Selectivity filter                                                                            Gly144   108.6   63.0    92.7
  Phe145                                                                                        109.7    64.7    98.4    
  Gly146                                                                                        118.5    76.5    127.4   
                                                                                                                         
  Modulator pocket                                                                              Phe134   139.3   74.0    104.1
  Lys271                                                                                        181.9    83.0    116.1   
  Trp275                                                                                        156.5    69.9    103.2   
                                                                                                                         
  Channel core                                                                                           132.4   83.5    118.8

  Extended Data Table 2b. Structural comparisons with K~2p~2.1 (TREK-1)                                               
  ----------------------------------------------------------------------- ----------------------------------- ------- -------
  5VKN                                                                    K~2p~ 2.1(TREK-1):ML335             0.443   0.388
  5VKP                                                                    K~2p~ 2.1(TREK-1):ML402             0.462   0.426
  4XDK                                                                    K~2p~ 10.1 (TREK-2):Norfluoxetine   1.976   1.317
  4BW5                                                                    K~2p~ 10.1(TREK-2):M4 up            1.054   0.918
  4XDJ                                                                    K~2p~ 10.1(TREK-2):M4 down          1.790   1.331
  419W                                                                    K~2p~ 4.1(TRAAK)                    1.176   1.141
  3UM7                                                                    K~2p~ 4.1(TRAAK) (no domain swap)   1.468   1.390
  4RUF                                                                    K~2p~ 4.1(TRAAK) W262S              1.351   1.288
  4RUE                                                                    K~2p~ 4.1(TRAAK) G124I              1.466   1.490
  4WFF                                                                    K~2p~ 4.1(TRAAK) M4 down            1.155   1.217
  4WFE                                                                    K~2p~ 4.1(TRAAK) M4 up              1.149   1.023
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###### 

**Extended Data Video V1** Morph between the K~2P~2.1(TREK-1) and K~2P~2.1(TREK-1):ML335 structures. K~2P~2.1(TREK-1) subunit chains are colored orange and smudge. ML335 is shown in yellow sticks. Residues His126, Phe134, Asn147, Lys271, and Trp275 from the orange subunit are shown as sticks.
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![K~2P~2.1(TREK-1) structures\
**a,** K~2P~2.1(TREK-1)~cryst~ cartoon (smudge and light orange) smudge subunit extracellular cap domain (CAP), M1--M4 transmembrane helices, C-tail, and V321 are labeled. **b,** K~2P~ modulator pocket cutaway. Cutouts display ML335 and ML402 F~o~-F~c~ densities (3.0σ). ML335, ML402, and Selectivity Filter 1 (SF1) are sticks. **c,** and **d**, Extracellular views excluding the CAP domain of **c,** ML335 and **d,** ML402 binding sites. ML335 and ML402 are space filling. Selectivity filter sidechains are sticks. **e,** Wire representation comparing K~2P~2.1(TREK-1):ML335 (smudge and light orange) and K~2P~10.1(TREK-2):norfluoxetine^[@R6]^ (light pink and magenta) binding sites. K~2P~2.1(TREK-1) P1 and P2 are cylinders. ML335 (yellow) and norfluoxetine (NorFx) (red) are space filling. In all panels select residues and channel elements are indicated, and where present, grey lines indicate the membrane.](nihms876351f1){#F1}

![K~2P~2.1(TREK-1) activator interactions\
Cartoon diagram of **a,** K~2P~2.1(TREK-1):ML335 and **b,** K~2P~2.1(TREK-1):ML402 interactions. Electrostatic and hydrogen bond interactions are black. Cation-π and π-π interactions are grey. **c,** and **d**, comparison of K~2P~2.1(TREK-1) (smudge) with **c,** K~2P~2.1(TREK-1):ML335 (deep salmon) and **d**, K~2P~2.1(TREK-1):ML402 (cyan).](nihms876351f2){#F2}

![K~2P~2.1(TREK-1) C-tail and lipid binding sites\
**a,** K~2P~2.1(TREK-1) C-tail. Positively charged residues are blue. S300A and E306A, a site having slight distortion from helical geometry, are magenta. **b,** K~2P~2.1(TREK-1) Electrostatic surface potential. Orange box highlights M1/M2/M4 junction. Cytoplasmic view (left) indicates C-tail positively charged patch. **c,** Lipids L1, L2, and L3 (cyan and white) shown as space filling. ML335 (yellow) is indicated. Insets show lipid binding pocket details.](nihms876351f3){#F3}

![K~2P~2.1(TREK-1) activator function\
Exemplar current traces for **a,** K~2P~2.1(TREK-1) (black) with 20 μM ML335 (purple). **b,** K~2P~4.1(TRAAK) (black) with 50 μM ML335 (orange). **c,** ML335 dose response curves for K~2P~2.1(TREK-1) (black), EC~50~=14.3 ± 2.7 μM (n≥5); K~2P~2.1(TREK-1) K271Q (blue filled circles); K~2P~4.1(TRAAK) (orange); K~2P~4.1(TRAAK) Q258K (green) EC~50~=16.2 ± 3.0 μM (n≥4); and ML335a: K~2P~2.1(TREK-1) (black open triangles). Exemplar current traces for **d,** K~2P~2.1(TREK-1) (black) with 20 μM ML402 (purple). **e,** K~2P~4.1(TRAAK) (black) with 50 μM ML335 (orange). **f,** ML402 dose response curves for K~2P~2.1(TREK-1) (black), EC~50~=13.7 ± 7.0 μM (n≥3); K~2P~2.1(TREK-1) K271Q (blue); K~2P~2.1(TREK-1) (blue); K~2P~4.1(TRAAK) (orange); K~2P~4.1(TRAAK) Q258K (green) EC~50~=13.6 ± 1.5 μM (n≥3). **g--j,** Exemplar current traces and voltage-current relationships for indicated K~2P~s in HEK293 inside-out patches in 150 mM K^+^~\[out\]~/150 mM Rb^+^~\[in\]~ for **g**, K~2P~2.1(TREK-1), **h**, K~2P~2.1(TREK-1) with 5 μM ML335, **I,** K~2P~2.1(TREK-1) with 5 μM ML402, and **j**, K~2P~2.1(TREK-1) G137I. **k,** Rectification coefficients (I~+100mV~/I~--100mV~) from recordings (n≥3) made in '**g--j'. l,** TREK activation model. Grey lines indicate mobile P1 (tan) and M4 (blue). C-type activators (orange), stabilize the selectivity filter and channel 'leak mode'. Potassium ions are purple. Gap in arrows indicates current flow intensity. Membrane is grey.](nihms876351f4){#F4}

[^1]: Correspondence and requests for material should be made to D.L.M.
